Motley Fool

Jazz Pharma is not the most popular drugmaker, but it is definitely worth a second look.

These fundamentally strong stocks are about to get even more attractive in the second half of 2021.

Teladoc Health was the first mover, but it’s no longer top dog by some standards.

The future is renewables, but fossil fuels remain the dominant source of energy. Should dividend investors focus on the…

These rock-solid income stocks pay yields ranging from 4.1% to as high as 10.2%.

Once again, their high efficacy could mean more market share.

History is not the market’s friend in the near term, but it’s a big-time ally of long-term investors.

Will the streaming leader join the 12-zero club within the next decade?

Another rough day for stocks could be a sign that the overdue correction is finally materializing.

It’s already well on its way, but the road ahead will be long.